Expedition Therapeutics

Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide.

The therapy is designed to target neutrophilic inflammation, a novel and clinically validated pathway that is a major driver of tissue damage, airway remodeling, and progressive decline in lung function.

The company's lead candidate, EXPD-101, is a potent, oral, once-daily DPP1 inhibitor being developed for COPD, with the potential to deliver continuing improvement for millions of patients who currently have no disease-controlling treatment options.